Sermo Reports on Hydroxychloroquine Efficacy, Rise in Prophylaxis Use; Over 80% Expect 2nd Outbreak NEW YORK–(BUSINESS WIRE)–Apr. 02, 2020 Widespread[…]
Read more
Category: Biomedical
Aptorum Group Collaborates with Covar Pharmaceuticals To Investigate at Least 3 Repurposed Drug Candidates (SACT-COV19) for Coronavirus Disease 2019 (COVID-19) under Existing Smart-ACT™ Platform and Acticule Infectious Disease Platform
NEW YORK–(BUSINESS WIRE)–Mar. 30, 2020 Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of[…]
Read more
NTHU’s Boron Neutron Capture Therapy Center Begins Treating Overseas Brain Cancer Patients
HSINCHU, Taiwan–(BUSINESS WIRE)–Mar. 25, 2020 On February 14th the melodious strains of the fourth movement of Mahler's Fifth Symphony were[…]
Read more
New Treatment for Parkinson’s Disease Developed at NTHU
HSINCHU, Taiwan–(BUSINESS WIRE)–Mar. 12, 2020 Ultrasound is widely used for conducting physical examinations, and plans are underway for expanding its[…]
Read more
Takeda Agrees to Divest Select OTC and Non-Core Assets in Latin America to Hypera Pharma for $825 Million USD
− Company further sharpens focus on patient access to innovative medicines in Latin America − Transaction further accelerates deleveraging OSAKA, Japan–(BUSINESS WIRE)–Mar.[…]
Read more
Takeda Completes Sale of Select OTC and Non-Core Assets to Acino
OSAKA, Japan–(BUSINESS WIRE)–Mar. 02, 2020 Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of[…]
Read more
New Cancer Treatment Developed at NTHU
HSINCHU, Taiwan–(BUSINESS WIRE)–Feb. 27, 2020 A research team led by Dr. Yunching Chen and Tsai-Te Lu of National Tsing Hua[…]
Read more
Aptorum Group Commences Commercialization of Dioscorea Opposita Bioactive Nutraceutical Tablets and Signed Sales Distribution Agreement in Hong Kong
NEW YORK–(BUSINESS WIRE)–Feb. 24, 2020 Aptorum Group Limited (“Aptorum Group”), a pharmaceutical company focused on the development of novel therapeutics[…]
Read more
Aptorum Group Announces Significant Progress of Repurposed Drug Candidate SACT-1 for Neuroblastoma Targeting IND Submission in H2 2020
NEW YORK–(BUSINESS WIRE)–Feb. 10, 2020 Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of[…]
Read more
Aptorum Group Announces Further Positive Data For Its ALS-4 Small Molecule Anti-virulence (Non-bactericidal) Drug Candidate For The Treatment of Infections Caused By Staphylococcus Aureus and On Track Targeted For IND Submission in H2 2020
NEW YORK–(BUSINESS WIRE)–Feb. 10, 2020 Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of[…]
Read more